ERBB2 and breast carcinoma: Functional relationships were assessed in a human breast cancer setting by treating immunocompromised mice bearing patient-derived xenografts (PDXs) established from two ERBB2+ tumors with the SFK inhibitor Dasatinib or the active site-directed mTOR inhibitor AZD2014, both of which are currently involved in multiple clinical trials.